Effect of reversible pulmonary hypertension on outcomes after heart transplantation

被引:28
作者
Drakos, Stavros G.
Kfoury, Abdallah G.
Gilbert, Edward M.
Horne, Benjamin D.
Long, James W.
Stringham, James C.
Campbell, Beverly A.
Renlund, Dale G.
机构
[1] Latter Day St Hosp, Cardiac Transplant Program, Utah Transplantat Affiliated Hosp, Salt Lake City, UT 84143 USA
[2] Univ Utah, Sch Med, Salt Lake City, UT USA
[3] George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA
关键词
D O I
10.1016/j.healun.2007.01.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Conflicting data exist regarding the impact of reversible pulmonary hypertension (PHTN) on post-transplant (Tx) outcomes. In this study we sought to determine the influence of reversible PHTN on outcomes after Tx. Methods: We retrospectively reviewed the records of adult patients who underwent heart Tx from 1993 to 2002. Patients were grouped depending on their measured pulmonary vascular resistance (PVR). Group 1 patients had a pre-Tx pulmonary vascular resistance (PVR) of < 3 Wood units (WLT). Patients with reversible PHTN, defined as pre-Tx PVR >= 3 Vru and reversing to < 3 Vru either with sub-lingual or intravenous vasodilatory agents, were divided into two groups based on their PVR before the reversibility test (PVR: Group 2, 3 to 4.5 Wu; Group 3, > 4.5 WLT). Results: Records for 222 adult heart recipients were reviewed (Group 1, n = 171; Group 2, n = 35; Group 3, n = 16). Baseline clinical characteristics (age, gender, heart failure etiology, history of diabetes, ischemic time, donor age and gender) were similar in the three groups and the average follow-up was 58 months. One-month and 1-year mortality (Groups 1, 2 and 3: 2%, 0% and 13%; and 8%, 0% and 13%, respectively) did not differ significantly between groups. Actuarial mortality was assessed using Cox regression analysis, adjusted for age and gender, and no increased risk of death was demonstrated for patients with reversible PHTN (for Group 2: multivariate hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.17 to 1.32,p = 0.15; for Group 3: HR 0.98, CI 0.34 to 2.84,p = 0.97). No differences were observed between the three groups for various post-Tx events, such as hospital stay, ICU stay, extubation time, transfusions, acute allograft dysfunction, acute hepatic dysfunction, acute and chronic renal dysfunction, infections, neurologic complications, gastrointestinal complications and coronary allograft vasculopathy. Conclusions: Reversible pulmonary hypertension is associated with similarly good post-transplant survival outcomes and morbidity, regardless of severity.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 20 条
[1]   PULMONARY-HYPERTENSION PREDICTS MORTALITY AND MORBIDITY IN PATIENTS WITH DILATED CARDIOMYOPATHY [J].
ABRAMSON, SV ;
BURKE, JF ;
KELLY, JJ ;
KITCHEN, JG ;
DOUGHERTY, MJ ;
YIH, DF ;
MCGEEHIN, FC ;
SHUCK, JW ;
PHIAMBOLIS, TP .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (11) :888-895
[2]   Is partially reversible pulmonary hypertension a contraindication for heart transplantation? [J].
Baldovinos, A ;
Kalangos, A ;
Sierra, J ;
Licker, MJ ;
Faidutti, B .
TRANSPLANTATION PROCEEDINGS, 2000, 32 (02) :468-469
[3]  
BOURGE RC, 1993, J HEART LUNG TRANSPL, V12, P549
[4]   Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation [J].
Butler, J ;
Stankewicz, MA ;
Wu, J ;
Chomsky, DB ;
Howser, RL ;
Khadim, G ;
Davis, SF ;
Pierson, RN ;
Wilson, JR .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (02) :170-177
[5]   Pulmonary hypertension and exercise intolerance in patients with heart failure [J].
Butler, J ;
Chomsky, DB ;
Wilson, JR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (06) :1802-1806
[6]  
Carrier M, 1998, CAN J CARDIOL, V14, P703
[7]   Reevaluating the significance of pulmonary hypertension before cardiac transplantation: Determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality [J].
Chen, JM ;
Levin, HR ;
Michler, RE ;
Prusmack, CJ ;
Rose, EA ;
Aaronson, KD .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1997, 114 (04) :627-634
[8]   SELECTION AND TREATMENT OF CANDIDATES FOR HEART-TRANSPLANTATION - A STATEMENT FOR HEALTH-PROFESSIONALS FROM THE COMMITTEE ON HEART-FAILURE AND CARDIAC TRANSPLANTATION OF THE COUNCIL ON CLINICAL CARDIOLOGY, AMERICAN-HEART-ASSOCIATION [J].
COSTANZO, MR ;
AUGUSTINE, S ;
BOURGE, R ;
BRISTOW, M ;
OCONNELL, JB ;
DRISCOLL, D ;
ROSE, E .
CIRCULATION, 1995, 92 (12) :3593-3612
[9]   INFLUENCE OF PREOPERATIVE PULMONARY-ARTERY PRESSURE ON MORTALITY AFTER HEART-TRANSPLANTATION - TESTING OF POTENTIAL REVERSIBILITY OF PULMONARY-HYPERTENSION WITH NITROPRUSSIDE IS USEFUL IN DEFINING A HIGH-RISK GROUP [J].
COSTARDJACKLE, A ;
FOWLER, MB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (01) :48-54
[10]   Reversibility of pulmonary hypertension in patients evaluated for orthotopic heart transplantation: Importance in the postoperative morbidity and mortality [J].
Espinoza, C ;
Manito, N ;
Roca, J ;
Castells, E ;
Mauri, J ;
Ribas, M ;
Claret, G .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (06) :2503-2504